Dengue Envelope-4 32kDa
Description
Production and Purification
The protein is synthesized in E. coli using recombinant DNA technology, followed by chromatography-based purification . Advantages of this system include:
-
Cost-effectiveness: Suitable for large-scale manufacturing .
-
Non-glycosylated: Simplifies production but may limit antibody recognition compared to mammalian-cell-derived E proteins .
Diagnostic Applications
The 32kDa antigen is primarily used in lateral flow assays and ELISAs to detect DENV-4-specific IgG/IgM antibodies . Key findings:
-
Sensitivity: DENV-4 E protein-based ELISA showed 31–50% sensitivity in clinical samples .
-
Cross-Reactivity: Reduced compared to full-length E protein, as DIII (a major cross-reactive epitope) is excluded .
-
Utility in Multiplex Assays: Often combined with antigens from DENV-1, -2, and -3 for comprehensive serotyping .
Limitations and Future Directions
-
Limited Neutralization Data: The 32kDa antigen does not elicit neutralizing antibodies, which primarily target DIII .
-
Serotype-Specific Gaps: Sensitivity for DENV-4 remains lower than for DENV-1 in ELISA formats .
-
Next-Generation Designs: Hybrid antigens combining DI/DII with DIII may improve diagnostic accuracy .
Product Specs
Purified by proprietary chromatographic technique.
Product Science Overview
Dengue fever is a mosquito-borne viral infection caused by one of the four closely related serotypes of the dengue virus (DENV), which belong to the genus Flavivirus and the family Flaviviridae. The four serotypes are DENV-1, DENV-2, DENV-3, and DENV-4. Infection with one serotype provides lifelong immunity to that specific serotype but only partial and temporary protection against the others. Subsequent infections with different serotypes increase the risk of severe dengue, also known as dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS).
DENV-4 is one of the four serotypes of the dengue virus. It is less commonly associated with severe disease compared to DENV-2 and DENV-3, but it can still cause significant morbidity and mortality. The envelope (E) protein of the dengue virus is a key structural protein involved in virus entry into host cells. It is also the primary target for neutralizing antibodies and is crucial for vaccine development.
The recombinant Dengue Virus Subtype 4 Envelope 32kDa protein is a laboratory-produced protein that mimics the natural envelope protein of the DENV-4. This recombinant protein is typically produced in Escherichia coli (E. coli) and is fused with a 6xHis tag for purification purposes. The protein contains domains I and II of the dengue envelope, which are essential for its immunogenic properties .
The recombinant DENV-4 envelope protein is produced using recombinant DNA technology. The gene encoding the envelope protein is cloned into an expression vector, which is then introduced into E. coli cells. The bacteria are cultured, and the recombinant protein is expressed. The protein is then purified using chromatographic techniques to achieve a purity of over 95%, as determined by polyacrylamide gel electrophoresis (PAGE) with Coomassie staining .
The recombinant DENV-4 envelope protein is used in various research and diagnostic applications. It is commonly used in enzyme-linked immunosorbent assays (ELISA) and lateral flow assays to detect antibodies against DENV-4 in patient samples. These assays are crucial for the diagnosis of dengue fever and for epidemiological studies. Additionally, the recombinant protein is used in vaccine research to develop subunit vaccines that can elicit a protective immune response without causing disease .
